Board meeting set for November 5 to approve Q2 and H1 results

Results View source PDF Explain this filing

ABBOTINDIA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹25295.00

prior close

₹25490.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.9%+0.2% vs market

Pharmaceuticals peers, median of 173sector+2.0%-0.9% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.7

15m

-0.7

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.9+0.2+2.0-0.9

Next day

+4.3pendingpending+2.6+1.7

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Abbott India's Board will meet on November 5, 2026, to approve unaudited financial results for the second quarter and six months ended September 30, 2026. The company's trading window remains closed from October 1 to November 7, 2026. No financial figures were disclosed.

Likely market impact

No results figures were disclosed. Stock sentiment may react to the revenue, profit and margin numbers announced on November 5.